NAFLD&NASH to HCC PBC&PSC to HCC The highly activated ACTA2, AIFM1, APP, ACTB, ADRB2, APP, network biomarkers EGFR, GRB2, NEDD8, CSNK2A1, EGFR, for potential SHC1, TUBA1C, TUBB6, HUWE1,
LMNB1, PCK1, inhibition strategy IL4R, GPR37, FRAT2, PPP2CA, SMAD5, of drug design HIST2H2BE, HSPB1, TSC22D1, ESR1, PGR, ZNF480, TIMP1, RYR2, FRAT2, ALDOB, ZYX, YBX1, HIST2H2BE, ZNF480, TP53, STAT5A, AR, H3F3A, TIMP1, ALDOB, TELO2, PXN, TBP, IGF2, AR, TP53, SRF, REPIN1, HSF1, ETS1, NRF1, STAT5A, STUB1, RFC5, RPL30, RPL23A, SP1, SP3, TRMT1, GSK3B, UBC, CEBPA, BPTF, ETS1, ALB, and MIR21 MDC1, RFC5, RPL30, TRMT1, UBC, GSK3B, TF, and MIR21 The repressed ALK and GATA1 CEBPE and GATA1 network biomarkers for potential activation strategy of drug design
In this study, it was found that peptidylprolyl isomerase A (PPIA), similar to peptidylprolyl isomerase A isoform 1 (LOC654188), transgelin 2 (TAGLN2), and isoform long of 14-3-3 protein beta/alpha (YWHAB) were downregulated, and lamin B1 (
LMNB1), Annexin A2 (ANXA2), and Annexin A2-like protein (ANXA2P2) were upregulated in low versus high BMD subjects [40].